- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.06. | FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use | ||
| 18.06. | Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade | ||
| 18.06. | Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes | ||
| 18.06. | Orion and Glykos extend ADC collaboration | ||
| 18.06. | FDA creates new priority review voucher scheme to boost US interests | ||
| 18.06. | Lisata collaborates with GATC Health on drug development | ||
| 18.06. | Genomics to roll out predictive clinical test across UK | ||
| 17.06. | Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn | ||
| 17.06. | AI-powered orchestration: Bringing the benefits to personalized therapy | ||
| 17.06. | European pharma needs scalable models to succeed in US | ||
| 17.06. | Averoa secures EC authorisation for oral CKD treatment | ||
| 17.06. | European biotech ecosystem takes aim at changing the funding narrative | ||
| 17.06. | Ex-ACIP panel warns of 'critically weakened' US immunisation programme | ||
| 17.06. | Teva to collaborate with Fosun Pharma for TEV-56278 | ||
| 17.06. | NextCure and Simcere partner to develop SIM0505 for solid tumours | ||
| 16.06. | Supernus makes depression drug play with $795m Sage buyout | ||
| 16.06. | FDA approves MSD's Keytruda to treat head and neck cancer | ||
| 16.06. | EHA 2025: AstraZeneca's surovatamig is potential next-gen BiTE for R/R B-ALL | ||
| 16.06. | Sarepta and Roche halt DMD gene therapy's use after second death | ||
| 16.06. | Ethris and Thermo Fisher partner on mRNA solutions | ||
| 16.06. | EHA 2025: Regeneron's Lynozyfic with Amgen's Kyprolis combo emerges for R/R MM | ||
| 16.06. | NICE approves GSK's belantamab mafodotin for blood cancer | ||
| 13.06. | AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal | ||
| 13.06. | Myasthenia gravis market to reach $10.3bn across 7MM by 2034 | ||
| 13.06. | Bharat Biotech acquires licence for GSK's Shigella vaccine development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .